According to a recent LinkedIn post from SeqOne, the company plans to participate in The 10+2 Santorini Conference, scheduled for May 26–29, 2026, in Santorini, Greece. The post highlights a talk by VP of Product Innovation, Preventive Medicine Jérôme Audoux on “Democratizing Pharmacogenomics: Bridging NGS, AI, and Clinical Practice,” set for May 28 at 1:10 PM.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post suggests SeqOne aims to position its offerings at the intersection of next-generation sequencing, artificial intelligence, and clinical workflows in pharmacogenomics. By emphasizing interpretability and real-world implementation of genomic data, the company appears to be targeting increased relevance in precision medicine and health tech, which could support longer-term adoption of its platform.
The post further indicates an interest in integrating pharmacogenomics into everyday clinical practice and scaling actionable insights from complex genomic datasets. For investors, this focus may signal a strategic push toward recurring clinical-use cases, potentially expanding SeqOne’s addressable market and strengthening its competitive positioning in clinical genomics.
Engagement at a specialized conference like Santorini 2026 may also provide networking and collaboration opportunities with researchers and clinicians. Such visibility could help validate SeqOne’s technology among key opinion leaders, which, if successful, may translate into partnerships, pilots, or commercialization pathways over time.